Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 50 and 80 years old (inclusive), of any gender
• People who have been diagnosed with Mild Cognitive Impairment or mild to moderate dementia caused by Alzheimer's disease, based on 2024 diagnostic guidelines
• People whose symptoms have lasted at least 6 months and have not improved after 3 or more months of standard treatment
• People whose score on a standard memory and thinking test (called the MMSE) falls between 12 and 26
• People who have had brain scan or spinal fluid tests confirming the presence of Alzheimer's-related proteins in the brain
• People who have a reliable caregiver who spends at least 3 hours per day with them
• People (or their legal representative) who have signed a written consent form agreeing to take part

Who may not be able to join:

• People for whom MRI scans, a specific eye/vessel imaging test (ICG angiography), or PET scans are not medically safe
• People for whom surgery or general anaesthesia is considered unsafe, such as those with blood clotting problems (confirm with trial site for specific blood test thresholds)
• People with serious problems affecting major organs, such as significantly reduced heart function, or severe liver or kidney disease (confirm with trial site for specific test thresholds)
• People whose MRI shows structural problems in the brain, such as tumours, strokes, bleeding, aneurysms, abnormal blood vessels, or fluid build-up
• People whose MRI shows significant signs of small vessel disease in the brain, including certain patterns of white matter changes or four or more small bleeds in the brain
• People whose dementia or memory problems are caused by something other than Alzheimer's disease, such as a thyroid condition or vitamin B12 deficiency
• People with a drug or alcohol addiction
• People with a severe psychiatric illness or who are considered at risk of suicide
• People who have another serious medical condition that means they are not expected to live longer than one year
• People who have taken part in another interventional clinical trial within the past 3 months
• People who the trial investigators consider unlikely to follow the trial requirements, or who are otherwise judged unsuitable for participation
• People currently receiving treatment with the medications Lecanemab or Donanemab
• People with any other condition the trial investigator considers unsuitable for participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.